Presentation of nonfinal results of randomized controlled trials at major oncology meetings

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3938-3944

  Booth, Christopher M ^a   Le Maître, Aurélie ^a   Ding, Keyue ^a   Farn, Kristen ^a   Fralick, Michael ^a   Phillips, Cameron ^a   Cescon, David W ^a   Meyer, Ralph M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CLINICAL RESEARCH; COLORECTAL CANCER; CONTROLLED STUDY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; ONCOLOGY; PRIORITY JOURNAL; PUBLICATION; SAMPLE SIZE; SCIENTIFIC LITERATURE; SYSTEMIC THERAPY; BREAST TUMOR; COLORECTAL TUMOR; DOCUMENTATION; LUNG TUMOR; NEOPLASM; ORGANIZATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL;

ABSTRACTING AND INDEXING AS TOPIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONGRESSES AS TOPIC; HUMANS; LUNG NEOPLASMS; LYMPHOMA; NEOPLASMS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69849113803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8771     Document Type: Article

References (16)

1. Fleming TR, Ellenberg S, DeMets DL: Monitoring clinical trials: Issues and controversies regarding confidentiality. Stat Med 21:2843-2851, 2002
2. Sackett DL, Naylor CD: Should there be early publication of ancillary studies prior to the first primary report of an unblinded randomized clinical trial? J Clin Epidemiol 46:395-402, 1993
3. Piantadosi S: Rigor in monitoring clinical trials is ethical. J Clin Oncol 26:683-685, 2008
4. Tam VC, Hotte SJ: Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. J Clin Oncol 26:2205-2211, 2008
5. Toma M, McAlister FA, Bialy L, et al: Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA 295: 1281-1287, 2006
6. Klassen TP, Wiebe N, Russell K, et al: Abstracts of randomized controlled trials presented at the society for pediatric research meeting: An example of publication bias. Arch Pediatr Adolesc Med 156:474-479, 2002
7. Bhandari M, Devereaux PJ, Guyatt GH, et al: An observational study of orthopaedic abstracts and subsequent full-text publications. J Bone Joint Surg Am 84-A:615-621, 2002
8. Weintraub WH: Are published manuscripts representative of the surgical meeting abstracts? An objective appraisal. J Pediatr Surg 22:11-13, 1987
9. Booth CM, Cescon DW, Wang L, et al: Evolution of the randomized controlled trial (RCT) in oncology over three decades. J Clin Oncol 26:5458-5464, 2008
10. Ridker PM, Torres J: Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 295:2270-2274, 2006
11. Clifford TJ, Barrowman NJ, Moher D: Funding source, trial outcome and reporting quality: Are they related? Results of a pilot study. BMC Health Serv Res 2:18, 2002
12. Rochon PA, Gurwitz JH, Simms RW, et al: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154:157-163, 1994
13. Green SJ, Fleming TR, O'Fallon JR: Policies for study monitoring and interim reporting of results. J Clin Oncol 5:1477-1484, 1987
14. Lan K, De Mets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
15. Girling D, Parmar M, Stenning S, et al: Clinical Trials in Cancer. Oxford, UK, Oxford University Press, 2007
16. Wells RJ: Secrecy and integrity in clinical trials. J Clin Oncol 26:680-682, 2008